Solutions for Metabolic Crosstalk in the TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology is committed to providing global collaborators with a full range of solutions and services to study the metabolic crosstalk in the tumor microenvironment (TME) to help you successfully achieve your research goals.
Tumor initiation and progression require metabolic reprogramming of cancer cells. Tumor cells automatically alter their fluxes through various metabolic pathways to meet increased bioenergetic and biosynthetic demands and mitigate oxidative stress required for cancer cell proliferation and survival. Metabolites mediate various intercellular crosstalk in TMEs. Moreover, the metabolism of cell types other than tumor cells (including endothelial cells, fibroblasts and immune cells) in the tumor microenvironment (TME) can regulate tumor initiation and progression.
The cell-autonomous mechanism is mainly a direct interaction between metabolite and protein components of the signaling pathway regulating the metabolite sensor pathway, which affects protein stability or activity and alters the regulation of the epigenome and epigenetic transcriptome. Alternatively metabolites released into TMEs signal to neighboring cells in a non-autonomous manner to mediate intercellular crosstalk.
The complex metabolic requirements of tumor cells with other cell types in the tumor microenvironment (TME) strongly suggest that successful targeting of tumor metabolism will need to be based on oncogene type, tumor type, TME composition, and metabolic symbiosis/crosstalk among cells in the TME.
Alfa Oncology has established an innovative technology platform for tumor microenvironment centers and is developing multiple technologies to provide high quality solutions and services to our global collaborators. Scientific experiments are designed to investigate how to inhibit tumor cell metabolism while focusing research on strategies for metabolic mechanisms in other cell types in TME. A comprehensive understanding of the complex mechanisms of interactions between cell types in the TME and the mechanisms of metabolic crosstalk will guide early trials, such as target engagement analysis and efficacy assessment.
Alfa Oncology uses single-cell metabolomics to distinguish individual cell types in the tumor microenvironment (TME) and to uncover their respective metabolic profiles and crosstalk. And single-cell metabolomics truly has a very large metabolite coverage, allowing for more rapid identification while enabling high-throughput assays. It is expected to be one of the most efficient tools for metabolic crosstalk studies of various cell types in the tumor microenvironment (TME).
To address the topic of metabolic crosstalk between various types of cells in TME, Alfa Oncology offers the technical service of single-cell multi-omics, which is the combination of multiple layers of information at single-cell resolution. Multi-omics technology is more powerful than single-level histological analysis, allowing a closer look at the dynamic changes between cells, a clearer identification of specific cells and their metabolites, unraveling the true meaning of each cell type, and the ability to dig deeper into biological mechanisms.
As one of the world's leading companies in the field of tumor microenvironment (TME) research, Alfa Oncology is committed to supporting researchers in making groundbreaking scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. With years of experience in the field of TME, we are ready to provide reliable solutions and quality services to our customers. If you have any special needs or questions, please feel free to contact us for support from our experienced experts.